- Home
- JHS vs SGMO Comparison
JHS vs SGMO Comparison
Compare JHS & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHS
- SGMO
- Stock Information
- Founded
- JHS 1973
- SGMO 1995
- Country
- JHS United States
- SGMO United States
- Employees
- JHS N/A
- SGMO N/A
- Industry
- JHS Finance Companies
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JHS Finance
- SGMO Health Care
- Exchange
- JHS Nasdaq
- SGMO Nasdaq
- Market Cap
- JHS 131.4M
- SGMO 122.8M
- IPO Year
- JHS N/A
- SGMO 2000
- Fundamental
- Price
- JHS $11.28
- SGMO $0.54
- Analyst Decision
- JHS
- SGMO Buy
- Analyst Count
- JHS 0
- SGMO 6
- Target Price
- JHS N/A
- SGMO $4.50
- AVG Volume (30 Days)
- JHS 32.8K
- SGMO 6.1M
- Earning Date
- JHS 01-01-0001
- SGMO 08-05-2025
- Dividend Yield
- JHS 3.96%
- SGMO N/A
- EPS Growth
- JHS N/A
- SGMO N/A
- EPS
- JHS 0.02
- SGMO N/A
- Revenue
- JHS N/A
- SGMO $63,756,000.00
- Revenue This Year
- JHS N/A
- SGMO N/A
- Revenue Next Year
- JHS N/A
- SGMO N/A
- P/E Ratio
- JHS $553.50
- SGMO N/A
- Revenue Growth
- JHS N/A
- SGMO 239.92
- 52 Week Low
- JHS $9.76
- SGMO $0.30
- 52 Week High
- JHS $11.25
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- JHS 52.11
- SGMO 54.59
- Support Level
- JHS $11.06
- SGMO $0.41
- Resistance Level
- JHS $11.18
- SGMO $0.51
- Average True Range (ATR)
- JHS 0.07
- SGMO 0.05
- MACD
- JHS 0.01
- SGMO 0.01
- Stochastic Oscillator
- JHS 72.50
- SGMO 74.39
About JHS John Hancock Income Securities Trust
John Hancock Income Securities Trust is a United States-based closed-ended diversified management investment company. Its primary objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.